MedPath

Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus

Not Applicable
Conditions
NAFLD
Type 2 Diabetes
Obesity
Dyslipoproteinaemia
Hypertension
Registration Number
NCT02459496
Lead Sponsor
German Institute of Human Nutrition
Brief Summary

Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although lifestyle modification and dietary treatment would be favourable.

The researchers therefore investigate dietary strategies such as low-carb and very-low calory diets regarding their potential to improve metabolism and body weight in (mostly) long-term T2DM patients.

Detailed Description

Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although lifestyle modification and dietary treatment would be favourable.

The researchers therefore investigate dietary strategies such as low-carb diets and very-low calory diets regarding their potential to improve metabolism and body weight in (mostly) long-term T2DM patients.

An intensive intervention of 3 weeks is followed by an 11-month maintenance phase to consolidate metabolic improvements.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • male and female subjects
  • 18-79 years old
  • type 2 diabetes
Exclusion Criteria
  • renal insufficiency
  • anaemia
  • immunosuppression
  • previous symptomatic cancer diagnosis
  • acute cardiovascular disease (stroke, coronary syndrome)
  • pregnancy and lactation
  • severe psychiatric disorders
  • corticoid or other immunosuppressive therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter3 weeks, 1 year

change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter

change in hepatic fat content (MR-S)3 weeks, 1 year

change in hepatic fat content (MR-S)

change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter3 weeks, 1 year

change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter

change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter3 weeks, 1 year

change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter

change in insulin secretion (glucagon stimulation test)3 weeks, 1 year

change in insulin secretion (glucagon stimulation test)

Secondary Outcome Measures
NameTimeMethod
change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)3 weeks, 1 year

autonomic neuropathy

inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level - IL-1; IL1beta, IL-6)3 weeks, 1 year

inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level)

change in parameters of peripheral - vibration threshold, thermal sensitivity and pain thresholds3 weeks, 1 year

peripheral neuropathy

Trial Locations

Locations (2)

German Institut for Human Nutrition; Department for Clinical Nutrition

🇩🇪

Bergholz-Rehbrücke, Brandenburg, Germany

German Institute for Human Nutrition, Department for Clinical Nutrition

🇩🇪

Berlin, Germany

German Institut for Human Nutrition; Department for Clinical Nutrition
🇩🇪Bergholz-Rehbrücke, Brandenburg, Germany
Margrit Kemper, Dr. med.
Sub Investigator
Silke Hornemann
Sub Investigator
Christiana Gerbracht, Dr.
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.